Activin and Inhibin

BJE6-106 (B106) is a potent, selective 3 rd generation PKCδ inhibitor with an IC 50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC 50 =50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis . BJE6-106 (B106) possesses

BJE6-106 (B106) is a potent, selective 3 rd generation PKCδ inhibitor with an IC 50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC 50 =50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis . BJE6-106 (B106) possesses

BJE6-106 (B106) is a potent, selective 3 rd generation PKCδ inhibitor with an IC 50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC 50 =50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis . BJE6-106 (B106) possesses

BJE6-106 (B106) is a potent, selective 3 rd generation PKCδ inhibitor with an IC 50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC 50 =50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis . BJE6-106 (B106) possesses

BKI-1369 is a bumped kinase inhibitor (BKI) . BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC 50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369

BKI-1369 is a bumped kinase inhibitor (BKI) . BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC 50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369

BKI-1369 is a bumped kinase inhibitor (BKI) . BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC 50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369

BKI-1369 is a bumped kinase inhibitor (BKI) . BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC 50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369

BKI-1369 is a bumped kinase inhibitor (BKI) . BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC 50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369

Potent inhibitor of the LFA-1/ICAM interaction.

Potent inhibitor of the LFA-1/ICAM interaction.

Potent inhibitor of the LFA-1/ICAM interaction.